|
1
|
Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of cancer and cancer metastasis. Oncol
Lett. 10:1240–1250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li F and Zhang W: Role of traditional
Chinese medicine and its chemical components in anti-tumor
metastasis. J Cancer Res Ther. 10 Suppl 1:S20–S26. 2014. View Article : Google Scholar
|
|
3
|
Yang H, Liu J and Dou QP: Targeting tumor
proteasome with traditional Chinese medicine. Curr Drug Discov
Technol. 7:46–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi Y, Izumi Y, Matsutani N, Dejima
H, Nakayama T, Okamura R, Uehara H and Kawamura M: Optimized
magnitude of cryosurgery facilitating anti-tumor immunoreaction in
a mouse model of Lewis lung cancer. Cancer Immunol Immunother.
65:973–982. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu C, Wang Y, Xia Y, He S, Wang Z, Chen Y,
Shu Y and Jiang J: Wilms' tumor 1 enhances Cisplatin-resistance of
advanced NSCLC. FEBS Lett. 588:4566–4572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Gu JF, Zou X, Wu J, Zhang MH, Jiang
J, Qin D, Zhou JY, Liu BX, Zhu YT, et al: The anti-lung cancer
activities of steroidal saponins of P. polyphylla Smith var.
chinensis (Franch.) Hara through enhanced immunostimulation in
experimental Lewis tumor-bearing C57BL/6 mice and induction of
apoptosis in the A549 cell line. Molecules. 18:12916–12936. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang F, Xu L, Qu X, Zhao M, Jin B, Kang
J, Liu Y and Hu X: Synergistic antitumor effect of β-elemene and
etoposide is mediated via induction of cell apoptosis and cell
cycle arrest in non-small cell lung carcinoma cells. Mol Med Rep.
4:1189–1193. 2011.PubMed/NCBI
|
|
9
|
Journigan VB and Zaveri NT: TRPM8 ion
channel ligands for new therapeutic applications and as probes to
study menthol pharmacology. Life Sci. 92:425–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loh CH, Inbaraj BS, Liu MH and Chen BH:
Determination of chlorophylls in Taraxacum formosanum by
high-performance liquid chromatography-diode array detection-mass
spectrometry and preparation by column chromatography. J Agric Food
Chem. 60:6108–6115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma Y, Guo FC, Wang W, Shi HS, Li D and
Wang YS: K-ras gene mutation as a predictor of cancer cell
responsiveness to metformin. Mol Med Rep. 8:763–768. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weiss GJ, Ganeshan B, Miles KA, Campbell
DH, Cheung PY, Frank S and Korn RL: Noninvasive image texture
analysis differentiates K-ras mutation from pan-wildtype NSCLC and
is prognostic. PLoS One. 9:e1002442014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piva S, Ganzinelli M, Garassino MC, Caiola
E, Farina G, Broggini M and Marabese M: Across the universe of
K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des.
20:3933–3943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sunaga N, Shames DS, Girard L, Peyton M,
Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, et al:
Knockdown of oncogenic KRAS in non-small cell lung cancers
suppresses tumor growth and sensitizes tumor cells to targeted
therapy. Mol Cancer Ther. 10:336–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Young A, Lyons J, Miller AL, Phan VT,
Alarcón IR and McCormick F: Ras signaling and therapies. Adv Cancer
Res. 102:1–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dalpa E, Gourvas V, Soulitzis N and
Spandidos DA: K-Ras, H-Ras, N-Ras and B-Raf mutation and expression
analysis in Wilms tumors: Association with tumor growth. Med Oncol.
34:62017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JT Jr, Steelman LS and McCubrey JA:
Modulation of Raf/MEK/ERK kinase activity does not affect the
chemoresistance profile of advanced prostate cancer cells. Int J
Oncol. 26:1637–1644. 2005.PubMed/NCBI
|
|
19
|
Conery AR, Sever S and Harlow E:
Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal
stability by activating the GTPase dynamin during cytokinesis. Proc
Natl Acad Sci USA. 107:15461–15466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong L, Wu Z, Guo L, Li L, Zhao R, Zhu D
and Zhou Q: Metastasis suppressor Nm23-H1 inhibits STAT3 signaling
via a negative feedback mechanism. Biochem Biophys Res Commun.
434:541–546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujita Y, Fujiwara K, Zenitani S and
Yamashita T: Acetylation of NDPK-D regulates its subcellular
localization and cell survival. PLoS One. 10:e01396162015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qu L, Liang L, Su J and Yang Z: Inhibitory
effect of upregulated DR-nm23 expression on invasion and metastasis
in colorectal cancer. Eur J Cancer Prev. 22:512–522. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Radović S, Dorić M, Hukić A, Babić M,
Kuskunović S and Spahović N: Immunohistochemical expression and
significance of NM23 suppressor protein in primary gastric
adenocarcinoma. Bosn J Basic Med Sci. 13:72–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schlattner U, Tokarska-Schlattner M, Epand
RM, Boissan M, Lacombe ML, Klein-Seetharaman J and Kagan VE:
Mitochondrial NM23-H4/NDPK-D: A bifunctional nanoswitch for
bioenergetics and lipid signaling. Naunyn Schmiedebergs Arch
Pharmacol. 388:271–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Durán E, Cárdenas JM, Reina MA and Arriazu
R: Loss of Nm23 is associated with a more favorable tumor
microenvironment in patients with breast cancer. Histol
Histopathol. 30:345–352. 2015.PubMed/NCBI
|
|
26
|
Yokdang N, Nordmeier S, Speirs K, Burkin
HR and Buxton IL: Blockade of extracellular NM23 or its endothelial
target slows breast cancer growth and metastasis. Integr Cancer Sci
Ther. 2:192–200. 2015.PubMed/NCBI
|
|
27
|
Niitsu N: The association of nm23-H1
expression with a poor prognosis in patients with peripheral T-cell
lymphoma, not otherwise specified. J Clin Exp Hematop. 54:171–177.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Fu LJ, Liu XQ, Hu ZY, Jiang Y,
Gao RF, Feng Q, Lan X, Geng YQ, Chen XM, et al: nm23 regulates
decidualization through the PI3K-Akt-mTOR signaling pathways in
mice and humans. Hum Reprod. 31:2339–2351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fiore LS, Ganguly SS, Sledziona J, Cibull
ML, Wang C, Richards DL, Neltner JM, Beach C, McCorkle JR, Kaetzel
DM and Plattner R: c-Abl and Arg induce cathepsin-mediated
lysosomal degradation of the NM23-H1 metastasis suppressor in
invasive cancer. Oncogene. 33:4508–4520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
You J, Chang R, Liu B, Zu L and Zhou Q:
Nm23-H1 was involved in regulation of KAI1 expression in
high-metastatic lung cancer cells L9981. J Thorac Dis. 8:1217–1226.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu Y, Li Y, Zhao X, Dong D, Tang C, Li E
and Geng Q: Combined detection of the expression of Nm23-H1 and p53
is correlated with survival rates of patients with stage II and III
colorectal cancer. Oncol Lett. 13:129–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
